GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved ... The dispute centred around Gilead's triple-drug regimen Biktarvy, which is based on emtricitabine, tenofovir ...

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...

Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), ...

Gilead Sciences generates stellar profit margins ... However, Gilead's Genvoya (2015), Odefsey (2016), Descovy (2016), and Biktarvy (2018) launches push patent protection into the 2030s and ...